Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY(®) compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation

Biologics have become an important component of treatment strategies for a variety of diseases, but the immunogenicity of large immune complexes (ICs) and aggregates of biologics may increase risk of adverse events is a concern for biologics and it remains unclear whether large ICs consisting of int...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyuuma, Masanao, Kaku, Ayaka, Mishima-Tsumagari, Chiemi, Ogawa, Bunichiro, Endo, Mayumi, Tamura, Yunoshin, Ishikura, Kei-ichiro, Mima, Masashi, Nakanishi, Yutaka, Fujii, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141648/
https://www.ncbi.nlm.nih.gov/pubmed/37122706
http://dx.doi.org/10.3389/fimmu.2023.1149874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141648/
https://www.ncbi.nlm.nih.gov/pubmed/37122706
http://dx.doi.org/10.3389/fimmu.2023.1149874

Ejemplares similares